Research programme: 14-3-3 inhibitors - UniSA Ventures

Drug Profile

Research programme: 14-3-3 inhibitors - UniSA Ventures

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator University of South Australia
  • Developer UniSA Ventures; University of South Australia
  • Class Small molecules
  • Mechanism of Action 14-3-3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Wounds
  • Research Cancer

Most Recent Events

  • 04 Aug 2016 Research programme: 14-3-3 inhibitors - UniSA Ventures is available for licensing - http://www.itek.com.au/portfolio/health/item/14-3-3-inhibition-to-accelerate-wound-healing.html
  • 03 Aug 2016 Early research in Cancer in Australia (PO)
  • 03 Aug 2016 Preclinical trials in Wounds in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top